發(fā)布時間：2018-09-10 16:46

【摘要】：目的分析探究在大量蛋白尿免疫球蛋白A腎病的治療過程中應用環(huán)孢素A聯合糖皮質激素的臨床效果和安全性。方法隨機選取我院2015年6月-2017年6月收治的大量蛋白尿免疫球蛋白A腎病患者40例,將其隨機分成兩組,即對照組和觀察組,各20例,在對照組患者中采用甲潑尼龍進行治療,而在觀察組患者則采用對照組藥物的同時采用環(huán)孢素A,對比分析兩組患者的治療效果以及不良反應發(fā)生率。結果兩組患者在進行為期24周的治療后,相較于對照組,觀察組患者的病情完全緩解率較高,差異具有統計學意義(P0.05);而兩組患者在接受治療兩周后,觀察組患者的尿蛋白含量要明顯低于對照組,差異具有統計學意義(P0.05);在不良反應的發(fā)生率方面,對照組與觀察組差異不具備統計學意義(P0.05)。結論在大量蛋白尿免疫球蛋白A腎病的治療過程中應用環(huán)孢素A聯合糖皮質激素,不僅治療效果顯著,而且不良反應發(fā)生率較低,臨床應用價值較高。
[Abstract]:Objective to investigate the clinical efficacy and safety of cyclosporine A combined with glucocorticoid in the treatment of massive proteinuria immunoglobulin A nephropathy. Methods from June 2015 to June 2017, 40 patients with proteinuria immunoglobulin A nephropathy were randomly divided into two groups: control group (n = 20) and observation group (n = 20). Methylprednisolone was used in the control group. The patients in the observation group were treated with cyclosporine A as well as the control group. The therapeutic effect and the incidence of adverse reactions were compared between the two groups. Results after 24 weeks of treatment, the complete remission rate of patients in the observation group was higher than that in the control group (P0.05). The urine protein content in the observation group was significantly lower than that in the control group, the difference was statistically significant (P0.05); in the incidence of adverse reactions, the difference between the control group and the observation group was not statistically significant (P0.05). Conclusion the application of cyclosporine A combined with glucocorticoid in the treatment of massive proteinuria immunoglobulin A nephropathy is not only effective, but also has lower incidence of adverse reactions and higher clinical application value.
【作者單位】： 內蒙古民族大學附屬醫(yī)院;
【分類號】：R692.31

【相似文獻】

相關期刊論文 前10條

1 黃良,朱為國,程少杰,王宗發(fā);大劑量環(huán)孢素A沖擊治療兒童狼瘡性腎病綜合征[J];中華皮膚科雜志;2001年06期

2 朱俊利;;環(huán)孢素A治療難治性腎病綜合征23例臨床療效分析[J];現代中西醫(yī)結合雜志;2008年29期

3 郭和清;王晶t，

本文編號：2235029